Indaptus Therapeutics, Inc. Convertible Notes Payable
Indaptus Therapeutics, Inc. (INDP) had Convertible Notes Payable of $5.70 million as of 2025-06-30, per its 10-K filed 2026-03-17.
Financial Statements › Balance Sheet › Liabilities › Notes Payable
us-gaap:ConvertibleNotesPayable · last filed 2026-03-17
- 2025-06-30: Convertible Notes Payable $5.70M.
| Period end | Convertible Notes Payable |
|---|---|
| 2025-06-30 | $5.70M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |